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Editorial Comment 
Epinephrine Infusions During 
Antiarrhythmic Drug 
Evaluations: Toward a Better 
Understanding of Drug Activity* 
JOHN P. D1MARCO, MD, PHD, FACC 
Charlottesville, Virginia 
Serial electrophysiologic testing for the assessment of anti-
arrhythmic drug therapy has been widely used for > 15 years 
and is the recommended approach in patients with life-
threatening arrhythmias. Previous studies have shown that 
for every drug evaluated to date, patients in whom the agent 
suppresses induction of ventricular tachycardia have a lower 
recurrence rate of sustained arrhythmia than do patients in 
whom an arrhythmia can be induced on the discharge 
antiarrhythmic regimen. However, arrhythmia recurrences 
do occur, even in patients whose arrhythmias are suppressed 
by electrophysiologic criteria, for reasons that may be dif-
ficult to discern. Lack of compliance with an often complex 
drug schedule, changes in the nature or drug sensitivity of 
the original arrhythmia, development of new and different 
arrhythmias that may be resistant and transient alterations in 
neurohumoral or hemodynamic factors must all be consid-
ered as possible contributors to drug failure. 
The present study. In this issue of the Journal, Catkins et 
al. (1) examine the potential reversibility by catecholamine 
infusion of the antiarrhythmic effects of two commonly used 
agents, quinidine and amiodarone, in patients with inducible 
sustained ventricular tachycardia. After selected baseline 
measurements (sinus cycle length, QT interval and right 
ventricular effective refractory period) were obtained, pa-
tients received an infusion of epinephrine that produced a 
plasma epinephrine concentration similar to that seen during 
mild or maximal physical exertion or stress. Similar electro-
physiologic measurements during basal conditions and dur-
ing epinephrine infusions were made after oral therapy with 
quinidine and then amiodarone. The authors (1) report that 
epinephrine partially or completely reversed the effects of 
both quinidine and amiodarone on sinus cycle length and QT 
interval. However, decreases in ventricular effective refrac-
tory period in response to epinephrine were much smaller 
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during treatment with amiodarone than those observed in the 
baseline study or in the presence of quinidine. Even though 
catecholamine infusions have been reported (2,3) to reverse 
suppression of ventricular tachycardia induction by many 
class I antiarrhythmic agents, no such reversal was seen in a 
small number of patients whose tachycardia became nonin-
ducible during amiodarone therapy. 
Clinical significance. The results of this study are consis-
tent with prior observations. Reversibility of the electro-
physiologic effects of class I agents by catecholamine infu-
sions has been previously reported (2,3). Amiodarone 
possesses intrinsic noncompetitive beta-adrenergic blocking 
activity that appears early during the course of therapy (4) 
and should be maximal after 9 to 10 days of high dose 
(1,800 mg/day) therapy (4,5). Therefore, antagonism of the 
effects of epinephrine in amiodarone-treated patients is not 
surprising, but can this observation explain an assumed 
increased efficacy of amiodarone during long-term therapy? 
Amiodarone occupies a unique position in the therapy of 
serious ventricular arrhythmias for several reasons. Al-
though numerous adverse effects may occur during long-
term therapy, amiodarone is surprisingly well tolerated 
during the early phases of treatment. The drug's unusual 
pharmacokinetic profile allows once-a-day dosing after load-
ing and lack of patient compliance for even many days after 
a steady state has been reached entails only a modest risk of 
loss of efficacy. Because of the long loading period required 
to achieve full antiarrhythmic effects, amiodarone is most 
often used after prior drug failures and, in contrast to the 
pattern seen with other drugs, patients often continue taking 
it even if the arrhythmia remains inducible during treatment. 
No study has directly compared in a controlled fashion 
arrhythmia recurrence during amiodarone treatment versus 
that during treatment with other drugs. Catkins et al. (1) are 
correct that some studies have reported 2-year recurrence 
rates > 30% in patients with arrhythmias suppressed by 
antiarrhythmic drugs, but these results were found in early 
trials and the evaluation protocols used would now be 
considered prone to error (6). More recent data (7,8) do not 
suggest a major drug-specific difference in recurrence rates 
of arrhythmias controlled by the discharge regimen. With all 
drugs evaluated by current stimulation protocols, arrhyth-
mia recurrence rates in patients with suppression of induc-
tion appear to be <10% at 2 years. 
Should we then routinely use catecholamine infusion to 
aid in the short-term evaluation of antiarrhythmic drugs? 
The percent of drug failures in patients whose arrhythmia 
responds to therapy appears low enough to favor only 
selected use of catecholamine challenge in routine clinical 
practice. Current protocols may already be too rigorous, in 
that many patients treated with a drug that does not suppress 
ventricular tachycardia induction will remain arrhythmia 
free during long-term therapy with that agent. Amiodarone 
may be no different from other drugs in this regard (9). 




identifying potential drug failure in these patients if a marker 
for failure could be identified. It may also be possible to use 
catecholamine infusions to identify patients with a high 
potential for proarrhythmia, particularly with drugs such as 
flecainide or encainide that have significant use-dependent 
electrophysiologic effects. 
Conclusions. The observations in this study (1) are im-
portant. In addition to reversal of antiarrhythmic drug activ-
ity, beta-adrenergic activity has many potential detrimental 
effects on arrhythmias. As a group, beta-adrenergic blocking 
agents have been convincingly shown to decrease mortality 
in postmyocardial infarction patients and are also effective in 
preventing myocardial ischemia. The possible addition of a 
beta-adrenergic blocker to therapy with any antiarrhythmic 
drug without intensive beta-blocking properties should al-
ways be considered. 
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